계명대학교 의학도서관 Repository

Comparison of the efficacy and safety of tolterodine 2 mg and 4mg combined with an α-bIocker in men with lower urinary tract symptoms(LUTS) and overactive bladder : a randomized controlled trial

Metadata Downloads
Author(s)
Tae Heon KimWonho JungYoon Seok SuhSoonhyun YookHyun Hwan SungKyu-Sung Lee
Keimyung Author(s)
Jung, Won Ho
Department
Dept. of Urology (비뇨의학)
Journal Title
BJU International
Issued Date
2016
Volume
117
Issue
2
Keyword
Benign prostatic hyperplasiaOveractive bladderAnticholinergics
Abstract
Objective
To evaluate the efficacy and safety of low-dose (2 mg)
tolterodine extended release (ER) with an a-blocker compared
with standard-dose (4 mg) tolterodine ER with an a-blocker
for the treatment of men with residual storage symptoms
after a-blocker monotherapy.
Patients and Methods
The study was a 12-week, single-blind, randomized, parallelgroup,
non-inferiority trial that included men with residual
storage symptoms despite receiving at least 4 weeks of ablocker
treatment. Inclusion criteria were total International
Prostate Symptom Score (IPSS) ≥12, IPSS quality-of-life item
score ≥3, and ≥8 micturitions and ≥2 urgency episodes per
24 h. The primary outcome was change in the total IPSS
score from baseline. Bladder diary variables, patient-reported
outcomes and safety were also assessed.
Results
Patients were randomly assigned to addition of either 2 mg
tolterodine ER (n = 47) or 4 mg tolterodine ER (n = 48) to
a-blocker therapy for 12 weeks. Patients in both treatment
groups had a significant improvement in total IPSS score
( 5.5 and 6.3, respectively), micturition per 24 h ( 1.3 and
1.7, respectively) and nocturia per night ( 0.4 and 0.4,
respectively). Changes in IPSS, bladder diary variables, and
patient-reported outcomes were not significantly different
between the treatment groups. All interventions were well
tolerated by patients.
Conclusions
These results suggest that 12 weeks of low-dose tolterodine
ER add-on therapy is similar to standard-dose tolterodine ER
add-on therapy in terms of efficacy and safety for patients
experiencing residual storage symptoms after receiving ablocker
monotherapy.
Keimyung Author(s)(Kor)
정원호
Publisher
School of Medicine
Citation
Tae Heon Kim et al. (2016). Comparison of the efficacy and safety of tolterodine 2 mg and 4mg combined with an α-bIocker in men with lower urinary tract symptoms(LUTS) and overactive bladder : a randomized controlled trial. BJU International, 117(2), 307–315. doi: 10.1111/bju.13267
Type
Article
ISSN
1464-4096
DOI
10.1111/bju.13267
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/33390
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Urology (비뇨의학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.